We read with interest the recent correspondences from Hickey et al. [1] and Riou et al. [2] reporting bosutinib-associated pulmonary arterial hypertension (PAH) and pleural effusion. Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukaemia (CML). However, TKIs are associated with potentially serious lung complications, which are particularly associated with dasatinib; the incidence of dasatinib-induced pleural effusion ranges from 15% to 35% [3, 4]. Dasatinib-related PAH has been reported in ∼0.45% of dasatinib-treated patients [5]. Bosutinib (developed by Pfizer (New York, NY, USA) in 2015) is a second-generation TKI approved for patients with CML that is resistant or intolerant to imatinib, nilotinib or dasatinib [6]. Bosutinib can induce parenchymal, pleural and vascular lung disease http://ow.ly/qMiQ30dMVK5

中文翻译：

---

博舒替尼相关肺炎

我们饶有兴趣地阅读了 Hickey 等人最近的通信。[1] 和 Riou 等人。[2] 报告了博舒替尼相关的肺动脉高压 (PAH) 和胸腔积液。酪氨酸激酶抑制剂 (TKIs) 彻底改变了慢性粒细胞白血病 (CML) 的治疗方法。然而，TKI 与潜在的严重肺部并发症相关，尤其是与达沙替尼相关；达沙替尼诱发胸腔积液的发生率为 15% 至 35% [3, 4]。据报道，约 0.45% 的达沙替尼治疗患者出现达沙替尼相关 PAH [5]。博舒替尼（由辉瑞（Pfizer，纽约，纽约，美国）于 2015 年开发）是第二代 TKI，被批准用于对伊马替尼、尼罗替尼或达沙替尼耐药或不耐受的 CML 患者 [6]。博舒替尼可诱发实质、胸膜和血管性肺病 http://ow.